Meng-Lin Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Meng-Lin Cheng has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Dai Li
School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China
2 shared publications- Haili Zhu
Hubei Key Laboratory of Environmental Risks and Related Diseases Precision Control, School of Basic Medical Sciences, Hubei University of Science and Technology, Xianning, China
2 shared publications Yin-Di Hu
School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China
2 shared publicationsYuan-Fen Yue
Department of Pharmacy, Xianning Central Hospital, First Affiliated Hospital of Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China
2 shared publicationsChun-Xi Chen
Xishui Affiliated Hospital of Hubei University of Science and Technology, Huanggang, China
1 shared publicationDing-Wen Cheng
School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, China
1 shared publication
Latest Publications
- Open Access
- 11 April 2023
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 25 (6) , 1-12
Alleviating effect of lycorine on CFA‑induced arthritic pain via inhibition of spinal inflammation and oxidative stress
Chronic pain is the primary symptom of osteoarthritis affecting a patient's quality of life. Neuroinflammation and oxidative stress in the spinal cord contribute to arthritic pain and represent ideal targets for pain management. In the present study, a model of arthritis was established by intra‑articular injection of complete Freund's adjuvant (CFA) into the left knee joint in mice. After CFA inducement, knee width and pain hypersensitivity in the mice were increased, motor disability was impaired, spinal inflammatory reaction was induced, spinal astrocytes were activated, antioxidant responses were decreased, and glycogen synthase kinase 3β (GSK‑3β) activity was inhibited. To explore the potential therapeutic options for arthritic pain, lycorine was intraperitoneally injected for 3 days in the CFA mice. Lycorine treatment significantly reduced mechanical pain sensitivity, suppressed spontaneous pain, and recovered motor coordination in the CFA‑induced mice. Additionally, in the spinal cord, lycorine treatment decreased the inflammatory score, reduced NOD‑like receptor protein 3 inflammasome (NLRP3) activity and IL‑1β expression, suppressed astrocytic activation, downregulated NF‑κB levels, increased nuclear factor erythroid 2‑related factor 2 expression and superoxide dismutase activity. Furthermore, lycorine was shown to bind to GSK‑3β through three electrovalent bonds, to inhibit GSK‑3β activity. In summary, lycorine treatment inhibited GSK‑3β activity, suppressed NLRP3 inflammasome activation, increased the antioxidant response, reduced spinal inflammation, and relieved arthritic pain.
- 11 April 2023
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 25 (6) , 1-12
Open AccessAlleviating effect of lycorine on CFA‑induced arthritic pain via inhibition of spinal inflammation and oxidative stress
Chronic pain is the primary symptom of osteoarthritis affecting a patient's quality of life. Neuroinflammation and oxidative stress in the spinal cord contribute to arthritic pain and represent ideal targets for pain management. In the present study, a model of arthritis was established by intra‑articular injection of complete Freund's adjuvant (CFA) into the left knee joint in mice. After CFA inducement, knee width and pain hypersensitivity in the mice were increased, motor disability was impaired, spinal inflammatory reaction was induced, spinal astrocytes were activated, antioxidant responses were decreased, and glycogen synthase kinase 3β (GSK‑3β) activity was inhibited. To explore the potential therapeutic options for arthritic pain, lycorine was intraperitoneally injected for 3 days in the CFA mice. Lycorine treatment significantly reduced mechanical pain sensitivity, suppressed spontaneous pain, and recovered motor coordination in the CFA‑induced mice. Additionally, in the spinal cord, lycorine treatment decreased the inflammatory score, reduced NOD‑like receptor protein 3 inflammasome (NLRP3) activity and IL‑1β expression, suppressed astrocytic activation, downregulated NF‑κB levels, increased nuclear factor erythroid 2‑related factor 2 expression and superoxide dismutase activity. Furthermore, lycorine was shown to bind to GSK‑3β through three electrovalent bonds, to inhibit GSK‑3β activity. In summary, lycorine treatment inhibited GSK‑3β activity, suppressed NLRP3 inflammasome activation, increased the antioxidant response, reduced spinal inflammation, and relieved arthritic pain.
- Open Access
- 19 December 2022
- Published by SAGE Publications in Molecular Pain
- Vol. 18
Emodin alleviates arthritis pain through reducing spinal inflammation and oxidative stress
Chronic pain is the predominant problem for rheumatoid arthritis patients, and negatively affects quality of life. Arthritis pain management remains largely inadequate, and developing new treatment strategies are urgently needed. Spinal inflammation and oxidative stress contribute to arthritis pain and represent ideal targets for the treatment of arthritis pain. In the present study, collagen-induced arthritis (CIA) mouse model was established by intradermally injection of type II collagen (CII) in complete Freund’s adjuvant (CFA) solution, and exhibited as paw and ankle swelling, pain hypersensitivity and motor disability. In spinal cord, CIA inducement triggered spinal inflammatory reaction presenting with inflammatory cells infiltration, increased Interleukin-1β (IL-1β) expression, and up-regulated NOD-like receptor thermal protein domain associated protein 3 (NLRP3) and cleaved caspase-1 levels, elevated spinal oxidative level presenting as decreased nuclear factor E2-related factor 2 (Nrf2) expression and Superoxide dismutase (SOD) activity. To explore potential therapeutic options for arthritis pain, emodin was intraperitoneally injected for 3 days on CIA mice. Emodin treatment statistically elevated mechanical pain sensitivity, suppressed spontaneous pain, recovered motor coordination, decreased spinal inflammation score and IL-1β expression, increased spinal Nrf2 expression and SOD activity. Further, AutoDock data showed that emodin bind to Adenosine 5‘-monophosphate (AMP)-activated protein kinase (AMPK) through two electrovalent bonds. And emodin treatment increased the phosphorylated AMPK at threonine 172. In summary, emodin treatment activates AMPK, suppresses NLRP3 inflammasome response, elevates antioxidant response, inhibits spinal inflammatory reaction and alleviates arthritis pain.
- 19 December 2022
- Published by SAGE Publications in Molecular Pain
- Vol. 18
Open AccessEmodin alleviates arthritis pain through reducing spinal inflammation and oxidative stress
Chronic pain is the predominant problem for rheumatoid arthritis patients, and negatively affects quality of life. Arthritis pain management remains largely inadequate, and developing new treatment strategies are urgently needed. Spinal inflammation and oxidative stress contribute to arthritis pain and represent ideal targets for the treatment of arthritis pain. In the present study, collagen-induced arthritis (CIA) mouse model was established by intradermally injection of type II collagen (CII) in complete Freund’s adjuvant (CFA) solution, and exhibited as paw and ankle swelling, pain hypersensitivity and motor disability. In spinal cord, CIA inducement triggered spinal inflammatory reaction presenting with inflammatory cells infiltration, increased Interleukin-1β (IL-1β) expression, and up-regulated NOD-like receptor thermal protein domain associated protein 3 (NLRP3) and cleaved caspase-1 levels, elevated spinal oxidative level presenting as decreased nuclear factor E2-related factor 2 (Nrf2) expression and Superoxide dismutase (SOD) activity. To explore potential therapeutic options for arthritis pain, emodin was intraperitoneally injected for 3 days on CIA mice. Emodin treatment statistically elevated mechanical pain sensitivity, suppressed spontaneous pain, recovered motor coordination, decreased spinal inflammation score and IL-1β expression, increased spinal Nrf2 expression and SOD activity. Further, AutoDock data showed that emodin bind to Adenosine 5‘-monophosphate (AMP)-activated protein kinase (AMPK) through two electrovalent bonds. And emodin treatment increased the phosphorylated AMPK at threonine 172. In summary, emodin treatment activates AMPK, suppresses NLRP3 inflammasome response, elevates antioxidant response, inhibits spinal inflammatory reaction and alleviates arthritis pain.